Previous 10 | Next 10 |
home / stock / alpmy / alpmy news
Cytokinetics (NASDAQ: CYTK ) slumps 15% premarket on light volume in reaction to unsuccessful results from a Phase 2 clinical trial, FORTITUDE-ALS , evaluating reldesemtiv (CK-2127107) in patients with amyotrophic lateral sclerosis (ALS). More news on: Cytokinetics, Incorpor...
CHICAGO , May 5, 2019 /PRNewswire/ -- Astellas Pharma Inc. today announced results from the Phase 4, 12-week PLUS trial, the first large-scale, randomized trial in North America and Europe evaluating the efficacy and safety of mirabegron vs. placebo in men with overactive bladder...
Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c...
The U.S. Department of Justice (DOJ) announces settlements with Astellas Pharma ( OTCPK:ALPMY -2.9% ) and Amgen ( AMGN +0.7% ) over their alleged kickback schemes aimed at illegally paying Medicare beneficiaries' copays for certain medications. More news on: Astellas Pharma Inc....
NORTHBROOK, Ill. , April 3, 2019 /PRNewswire/ -- Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. Steven Benner , M.D., was promoted to president and Head of Development; Zhonghong Eric Gu...
Thinly traded micro cap Constellation Pharmaceuticals ( CNST -1.4% ) slips on average volume in response to results from the Phase 1b portion of a Phase 1/2 clinical trial, ProSTAR , evaluating CPI-1205, combined with Pfizer and Astellas' Xtandi (enzalutamide) or J & J's Zytiga (abi...
TOKYO , April 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA ® (gilteritinib) to salvage chemotherapy in adult patients with relapsed o...
By Bill Langbein, Founder SanaCurrents One of the strongest performing biopharmaceutical stocks this year is Evolus ( EOLS ). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then ...
BOTHELL, Wash. and TOKYO , March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced positive topline results from the first cohort of patients in a...
TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6 ) at ENDO 2019, the Endocr...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...